In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae

Mycoses

Volumn 45, Issue 5-6, 2002, Pages 166-169

  Lass Flörl, Cornelia ^a   Nagl, M ^a   Gunsilius, E ^a   Speth, C ^a   Ulmer, H ^b   Wurzner R ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Amphotericin B; Aspergillus; Colloidal dispersion; Liposomal formulation; Susceptibility assay

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SENSITIVITY; FUNGUS ISOLATION; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLUS; HUMANS; LIPOSOMES; MICROBIAL SENSITIVITY TESTS;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; FUNGI;

EID: 0036307427     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0507.2002.00748.x     Document Type: Article

References (18)

1. Pulmonary aspergillosis in the acquired immunodeficiency syndrome
2. Prolonged granulocytopenia, the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia
3. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host
4. Invasive aspergillosis
5. Impact of previous aspergillosis on the outcome of bone marrow transplantation
6. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
7. Nosocomial fungal infections, a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation
8. Studies of the in vitro activity of voriconazole and itraconazole against Aspergillus hyphae using viability staining
9. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi
10. Comparison of the in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholat, AB colloidal dispersion, liposomal AB, AB liquid complex and itraconazole
11. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
12. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B
13. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models
14. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients
15. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B
16. Comparative study of susceptibilities of germinated to ungerminated conidia of Aspergillus fumigatus to various antifungal agents
17. Antifungal susceptibility testing of pathogenic molds, effects of germination on the outcome of in vitro susceptibility to amphotericin B and itraconazole P 479
18. Lipid formulations of amphotericin B, clinical efficacy and toxicities